7:15 PM
 | 
Sep 26, 2013
 |  BC Extra  |  Clinical News

NovaRx's Lucanix misses NSCLC endpoint

NovaRx Corp. (San Diego, Calif.) said Lucanix belagenpumatucel-L plus best supportive care (BSC) as maintenance therapy missed the primary endpoint of improving median overall survival (OS) vs. placebo plus BSC in the Phase III STOP trial to treat advanced non-small...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >